Search Results - "Leonardi, C L"

Phase III randomized study of the proposed adalimumab biosimilar GP2017 in psoriasis: impact of multiple switches by Blauvelt, A., Lacour, J.‐P., Fowler, J.F., Weinberg, J.M., Gospodinov, D., Schuck, E., Jauch‐Lembach, J., Balfour, A., Leonardi, C.L.

“…Summary Background Adalimumab is used to treat several inflammatory diseases, including plaque psoriasis. GP2017 is a proposed adalimumab biosimilar…”
Get full text

Ixekizumab treatment for psoriasis: integrated efficacy analysis of three double‐blinded, controlled studies (UNCOVER‐1, UNCOVER‐2, UNCOVER‐3) by Papp, K.A., Leonardi, C.L., Blauvelt, A., Reich, K., Korman, N.J., Ohtsuki, M., Paul, C., Ball, S., Cameron, G.S., Erickson, J., Zhang, L., Mallbris, L., Griffiths, C.E.M.

“…Summary Background Ixekizumab, a high‐affinity monoclonal antibody that selectively targets interleukin (IL)‐17A, is approved for the treatment of…”
Get full text

Extension of ustekinumab maintenance dosing interval in moderate‐to‐severe psoriasis: results of a phase IIIb, randomized, double‐blinded, active‐controlled, multicentre study (PSTELLAR) by Blauvelt, A., Ferris, L.K., Yamauchi, P.S., Qureshi, A., Leonardi, C.L., Farahi, K., Fakharzadeh, S., Hsu, M.‐C., Li, S., Chevrier, M., Smith, K., Goyal, K., Chen, Y., Muñoz‐Elías, E.J., Callis Duffin, K.

“…Summary Background Phase III studies showed that some patients maintained response for ≥ 6 months following ustekinumab discontinuation. Objectives To assess…”
Get full text

Network meta‐analysis of biologic treatments for psoriasis using absolute Psoriasis Area and Severity Index values ≤1, 2, 3 or 5 derived from a statistical conversion method by Mrowietz, U., Warren, R.B., Leonardi, C.L., Saure, D., Petto, H., Hartz, S., Dossenbach, M., Reich, K.

“…Background In practice, the goal of treatment for patients with psoriasis is to achieve almost clear or clear skin and maintain disease control, regardless of…”
Get full text

The tumour necrosis factor-α inhibitor adalimumab rapidly reverses the decrease in epidermal Langerhans cell density in psoriatic plaques by Gordon, K.B., Bonish, B.K., Patel, T., Leonardi, C.L., Nickoloff, B.J.

“…Summary Background  The pathophysiology of psoriasis is poorly understood, and the mechanism of action of biological agents interfering with tumour necrosis…”
Get full text

Efalizumab‐induced autoimmune pancytopenia by Tom, W.L., Miller, M.D., Hurley, M.Y., Suneja, T., Kudva, G., Leonardi, C.L., Obadiah, J.M.

“…Summary Efalizumab is a recombinant, humanized monoclonal anti‐CD11a antibody used for the treatment of moderate to severe plaque psoriasis. Immune‐mediated…”
Get full text

Rapid improvements in health‐related quality of life and itch with ixekizumab treatment in randomized phase 3 trials: results from UNCOVER‐2 and UNCOVER‐3 by Leonardi, C.L., Blauvelt, A., Sofen, H.L., Gooderham, M., Augustin, M., Burge, R., Zhu, B., Reich, K.

“…Background Patients with moderate‐to‐severe psoriasis report impaired health‐related quality of life (HRQoL). Objective To assess speed of onset of…”
Get full text

Tildrakizumab efficacy and safety in patients with psoriasis and concomitant metabolic syndrome: post hoc analysis of 5‐year data from reSURFACE 1 and reSURFACE 2 by Fernandez, A.P., Dauden, E., Gerdes, S., Lebwohl, M.G., Menter, M.A., Leonardi, C.L., Gooderham, M., Gebauer, K., Tada, Y., Lacour, J.P., Bianchi, L., Egeberg, A., Pau‐Charles, I., Mendelsohn, A.M., Rozzo, S.J., Mehta, N.N.

“…Background Limited data are available on long‐term efficacy and safety of biologics in patients with psoriasis and metabolic syndrome (MetS), a common…”
Get full text

Long‐term optimization of outcomes with flexible adalimumab dosing in patients with moderate to severe plaque psoriasis by Gniadecki, R., Leonardi, C.L., Gordon, K.B., Gu, Y., Geng, Z., Nader, A., Teixeira, H.D.

“…Background The recently updated dosing recommendation for adalimumab for moderate to severe plaque psoriasis states that patients with inadequate response to…”
Get full text

A high level of clinical response is associated with improved patient-reported outcomes in psoriasis: analyses from a phase 2 study in patients treated with ixekizumab by Edson-Heredia, E., Banerjee, S., Zhu, B., Maeda-Chubachi, T., Cameron, G.S., Shen, W., Heffernan, M.P., Gordon, K.B., Leonardi, C.L.

Get full text

Cutaneous reactions following herpes zoster infections: report of three cases and a review of the literature by GIBNEY, M. DAVIS, NAHASS, G. T., LEONARDI, C. L.

Get full text

Role of Mycobacterium paratuberculosis in Crohn's disease: a prospective, controlled study using polymerase chain reaction by Clarkston, W K, Presti, M E, Petersen, P F, Zachary, Jr, P E, Fan, W X, Leonardi, C L, Vernava, 3rd, A M, Longo, W E, Kreeger, J M

“…Mycobacterium paratuberculosis has been proposed as a causative agent in patients with Crohn's disease. The purpose of this study was to determine whether M…”
Get more information

Detection of herpes simplex and varicella-zoster infection from cutaneous lesions in different clinical stages with the polymerase chain reaction by Nahass, George T, Mandel, Mitchell J, Cook, Sandra, Fan, Wei, Leonardi, Craig L

“…Background: The polymerase chain reaction (PCR) can be used to diagnose a variety of infectious processes. Objective: We sought to determine whether Tzanck…”
Get full text

Absence of human papillomavirus infection in cutaneous lichen planus by Boyd, Alan S., Leonardi, Craig L.

Get full text

Identification of Mycobacterium tuberculosis DNA in a case of lupus vulgaris by Serfling, U, Penneys, N S, Leonardi, C L

“…A variety of cutaneous lesions are believed to result from the presence of Mycobacterium tuberculosis. Demonstration of M. tuberculosis directly or in culture…”
Get more information

Dermatomal lichenoid chronic graft-vs-host disease following varicella-zoster infection despite absence of viral genome by Baselga, E, Drolet, B A, Segura, A D, Leonardi, C L, Esterly, N B

“…Localized cutaneous graft-versus-host disease (GVHD) following a dermatomal distribution or in a pattern of Blaschko's lines. Some authors have postulated that…”
Get more information

Cutaneous reactions following herpes zoster infections: report of three cases and a review of the literature by GIBNEY, M. DAVIS, NAHASS, G. T., LEONARDI, C. L.

“…Summary Three patients, one healthy and two immunocompromised, developed cutaneous reactions that histologically mimicked granuloma annulare at sites of…”
Get full text

Trichilemmomas are not associated with human papillomavirus DNA by Leonardi, C L, Zhu, W Y, Kinsey, W H, Penneys, N S

“…Trichilemmoma is considered a benign neoplasm derived from the outer root sheath of the hair follicle. Although the histogenesis of the lesion is unknown, a…”
Get more information

Interface dermatitis in acute varicella-zoster virus infection: demonstration of varicella-zoster virus DNA in keratinocytes by in situ polymerase chain reaction by Nahassf, G.T., Penneys, N.S., Leonardi, C.L.

Get full text

Concurrent herpes simplex and varicella-zoster infection in an immunocompromised patient by Gibney, Mary Davis, Leonardi, Craig L, Glaser, Dee Anna

Get full text